Whitehawk Therapeutics, Inc. (WHWK)
| Market Cap | 269.65M +246.8% |
| Revenue (ttm) | n/a -72.5% |
| Net Income | -79.83M |
| EPS | -1.10 |
| Shares Out | 57.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 226,165 |
| Open | 4.870 |
| Previous Close | 4.830 |
| Day's Range | 4.640 - 4.940 |
| 52-Week Range | 1.600 - 5.495 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 7.50 (+58.56%) |
| Earnings Date | Aug 6, 2026 |
About WHWK
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Financial Performance
In 2025, Whitehawk Therapeutics's revenue was $7.15 million, a decrease of -72.50% compared to the previous year's $25.98 million. Losses were -$20.60 million, -67.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for WHWK stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 58.56% from the latest price.
News
Whitehawk Therapeutics Earnings release: Q2 2026
Whitehawk Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Whitehawk Therapeutics Quarterly report: Q2 2026
Whitehawk Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of Ju...
Whitehawk Therapeutics Slides: Corporate presentation
Whitehawk Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Whitehawk Therapeutics initiated with an Outperform at Leerink
Leerink initiated coverage of Whitehawk Therapeutics (WHWK) with an Outperform rating and $9 price target
Whitehawk, Biocytogen collaborate for bispecific antibody ADC development
Biocytogen and Whitehawk Therapeutics (WHWK) announced a global collaboration to develop bispecific antibody-drug conjugates. Biocytogen will provide access to up to five bispecific antibodies using i...
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop ...
Whitehawk Therapeutics initiated with a Buy at B. Riley
B. Riley analyst Yuan Zhi initiated coverage of Whitehawk Therapeutics (WHWK) with a Buy rating and $10 price target Whitehawk is a clinical-stage oncology company advancing a three-asset, antibody-dr...
Whitehawk Therapeutics Transcript: AGM 2026
The meeting addressed three proposals, all of which passed, including director elections, executive compensation, and auditor ratification. No stockholder questions were received, and final voting results will be filed on Form 8-K.
Whitehawk Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three ADCs are advancing, with two in clinical trials and a third entering in Q3 2024, supported by unique linker technology and a recent $87.5M financing. The pipeline targets PTK7, MUC16, and SEZ6, aiming for high efficacy and improved tolerability, with data updates expected in 2027.
Whitehawk Therapeutics presents real-world analysis on SEZ6
Whitehawk Therapeutics (WHWK) announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure related homolog protein 6 with a next-generation ADC for the...
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for com...
Whitehawk Therapeutics Registration statement: Registration filing
Whitehawk Therapeutics filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology t...
Whitehawk Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The session highlighted a differentiated ADC platform with strong preclinical and early clinical data across three programs, leveraging a unique paired linker payload for enhanced stability and safety. External validation from partners and upcoming ASCO data further support the platform’s clinical promise.
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113,...
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology t...
Whitehawk Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Recent financing extends cash runway into 2028, supporting three ADC assets built on a differentiated CPT-113 linker payload. Lead programs target PTK7 and MUC16, aiming for best-in-class efficacy and safety, with key data readouts and external validation expected at upcoming congresses.
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology t...
Whitehawk Therapeutics announces $87.5M private placement
Whitehawk Therapeutics (WHWK) announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public...
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies...
Whitehawk Therapeutics price target raised to $7 from $6 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Whitehawk Therapeutics (WHWK) to $7 from $6 and keeps an Outperform rating on the shares after the company provided Q1…
Whitehawk Therapeutics reports Q1 EPS (32c), consensus (33c)
Reports Q1 revenue $0 vs. $7.14M last year. “This quarter reflects continued progress across our pipeline as we advance Phase 1 dose-escalation studies for HWK-007 and HWK-016, with a third…
Whitehawk Therapeutics Earnings release: Q1 2026
Whitehawk Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Whitehawk Therapeutics Quarterly report: Q1 2026
Whitehawk Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.